NPS Pharmaceuticals Inc. said partner GlaxoSmithKline plc prematurely halted a Phase II trial of osteoporosis drug Ronacaleret (SB-751689) after a planned interim analysis showed a lack of efficacy. (BioWorld Today)
The biotech industry tends to be somewhat resistant to macroeconomic forces, given the constant demand for healthcare. But the industry isn't totally insulated from the recent events on Wall Street, including Lehman's bankruptcy, Merrill Lynch's acquisition by Bank of America and the news that Goldman Sachs and Morgan Stanley are moving into commercial banking. (BioWorld Financial Watch)
Less than three months after selling preclinical hemophilia drug MAXY-VII to Bayer HealthCare in a deal worth up to $120 million, Maxygen Inc. is at it again. (BioWorld Today)
